Entities / Company
Merck.
public company in Indonesia
- Reports this week
- 19
- Active events
- 12
- Connections
- 235
What's happening
Reports per dayLast 90 days
90 days agoDrag either end to show only events that began in that periodToday
Active this week
-
Eli Lilly, Novo Nordisk, and Merck are currently competing in the highly competitive GLP-1 obesity market.Well supported3 reports
-
Merck will share clinical trial results at the American Academy of Ophthalmology (AAO) meeting.Some support1 report
-
Janus Henderson is backing biotech reverse mergers while dueling drug data emerges between involved companies.Some support2 reports
-
Bank of America led Merck's $5 billion financing deal, alongside bond sales by automakers, amid market anticipation of FED rate decisions.Some support1 report1 development inside
-
Bank of America shared insights from Merck's CMO regarding the ongoing financing deal.Some support1 report
-
Merck, a New Jersey-based drugmaker, was the subject of an RBC Capital Markets analysis regarding its drug showing non-inferiority to a competitor's product from Hoffmann-La Roche.Some support1 report
-
Merck faces sales challenges in China while simultaneously seeking FDA approval for new drugs.Some support2 reports
-
Merck is seeking FDA approval for its drug Winrevair, based on data from the ZENITH, HYPERION, and Stellar studies.Some support6 reports
-
RFK Jr.'s appointment as HHS Secretary is creating pressure as Medicare price setting and Part D redesign impact the sales and operations of major pharmaceutical companies including Pfizer, Amgen, J&J, Merck, and Eli Lilly.Speculative1 report2 developments inside
-
Pfizer, Johnson & Johnson, and Merck are facing significant industry pressures due to patent cliffs and market pricing demands.Some support1 report
-
Moderna and Merck announced a partnership on their mRNA cancer vaccine trial, leading to analyst rating hikes.Some support5 reports
-
Moderna and Merck jointly developed and presented intismeran autogene therapy at the ESMO Congress in Madrid.Well supported4 reports
Earlier this month
-
ISS research contributed to the formulation of Keytruda, a medical application involving Chief Engineer Ariel Ekblaw and Michael Roberts.Some support1 report
-
Pfizer, Merck, and Amgen are large-cap drugmakers with significant operations in the United States.Some support1 report1 development inside
-
Amgen and Merck are currently competing against each other in the market for investor capital.Some support3 reports
-
Medicare pricing negotiations are impacting major pharmaceutical companies, including AbbVie, Eli Lilly, and Merck, who are seeking pricing exemptions.Some support2 reports3 developments inside
-
Major pharmaceutical companies, including Pfizer, AstraZeneca, and Merck, announced several new partnerships and acquisitions in the oncology sector.Some support3 reports4 developments inside
-
Merck's Animal Health segment is performing well, and the company discussed transformation during a meeting with Morgan Stanley.Some support1 report
-
A market rally was observed in the biotech sector, driven by positive cancer vaccine news, causing Eli Lilly shares to rise.Some support2 reports
-
Eli Lilly, Merck, and Novo Nordisk are competing in the GLP-1 economics market, with Novo Nordisk referencing a SUSE cardiovascular trial.Some support3 reports
-
Moderna announced a collaboration with Merck KGaA regarding a personalized cancer vaccine platform.Well supported18 reports10 developments inside
-
OPKO Health announced asset sales, advanced an EBV vaccine Phase 1 trial, and saw FDA approval for prostate cancer screening.Well supported5 reports
-
Report covers clinical trials for Mycosis Fungoides involving Bristol-Myers Squibb, Johnson & Johnson, Merck, and Novartis.Some support3 reports1 development inside
-
Dr. Cannon gained experience at Merck, involving Lindus Therapeutics.Some support1 report
-
Moderna, Tempus, and Merck partnered on the INTerpath-001 trial, which focuses on indications that are covered by Medicare.Some support2 reports
-
Moderna and Merck announced a landmark moment in vaccine testing, alongside updates regarding personnel at Moderna and Columbia University.Some support1 report
-
Robert F. Kennedy Jr. collaborated on major cancer vaccine trials while criticizing mRNA technology and its potential funding.Some support2 reports
-
Merck's stock price increased following positive drug performance involving Summit Therapeutics.Some support1 report
-
Financial results and stock performance comparisons among AbbVie, Johnson & Johnson, Eli Lilly, and Merck.Some support2 reports1 development inside
-
Companies including UnitedHealth Group, Procter & Gamble, Abbott Laboratories, and Merck are noted as being included in high-quality dividend ETFs.Some support1 report1 development inside
-
The Schwab U.S. Dividend Equity ETF now includes Procter & Gamble, Abbott Laboratories, and Merck among its top 10 holdings.Some support1 report
-
Moderna and Merck are developing an experimental melanoma vaccine with partners, while concerns about AI models are impacting Gartner's business.Some support2 reports
-
Merck has set the list price for a drug that received approval from the FDA.Some support1 report
-
Moderna combined its vaccine with Merck's Keytruda drug.Some support3 reports
-
Moderna, Merck, and AbbVie are seeking new revenue streams to offset losses caused by patent expirations.Some support2 reports
One to three months ago
-
Berkshire Hathaway and Warren Buffett commented on the Moderna and Merck partnership, criticizing market speculation while noting positive news regarding the mRNA vaccine collaboration.Some support1 report
-
Moderna and Merck are seeking FDA review for a novel cancer treatment, having co-led a Phase 3 mRNA vaccine trial.Well supported13 reports1 development inside
-
Moderna and Merck announced initial results from a late-stage trial for their novel cancer treatment.Some support3 reports
-
Moderna, Merck, and Georgetown Lombardi Comprehensive Cancer Center are collaborating on developing a personalized cancer vaccine combination.Some support1 report
-
Moderna and Merck developed personalized mRNA cancer vaccine Intismeran following trial success, leading to a surge in Moderna's shares.Well supported7 reports2 developments inside
-
Moderna and Merck announced the successful outcome of their Phase 3 combined treatment trials involving a new cancer vaccine and Keytruda.Some support2 reports
-
Positive Phase 3 data announced from the combined treatment trials involving Moderna and Merck.Well supported3 reports
-
The new event is a composite of two unrelated stories: FED inaction on inflation and successful cancer therapy trial results involving Moderna and Merck.Some support2 reports
-
Positive interim readout reported for melanoma trials involving Moderna and Merck.Well supported4 reports
-
Healthcare stocks surged to record highs on August 19, 2026, amid market excitement over drug breakthroughs involving Moderna, Amgen, and Merck.Some support2 reports
-
Moderna and Merck are developing a combination therapy using Keytruda.Well supported7 reports
-
Moderna and Merck are developing cancer vaccines in partnership, while Moderna is also seeking approval for its seasonal influenza vaccine.Well supported33 reports2 developments inside
-
Novo Nordisk, Merck, and Eli Lilly are noted as large pharmaceutical rivals with recent drug approvals and market presence in the US.Some support3 reports3 developments inside
-
Andrew Wakefield recommended separating shots in 1998, noting that products would take Merck over a decade to develop.Some support1 report
-
Vaccine trial successes boosted Moderna and Merck, while investors awaited Fed minutes amid geopolitical uncertainty in the Middle East and disappointing OpenAI results.Some support1 report
-
Google gained permission to buy a $12B stake, coinciding with positive late-stage trial results for a cancer vaccine.Some support1 report1 development inside
-
Moderna and Merck co-developed an experimental cancer vaccine, while also forming a partnership regarding tensor processing units with Google and Marvell Technology.Some support2 reports
-
Moderna and Merck developed a new therapy.Some support8 reports
-
Moderna, Merck, and the National Cancer Institute announced successful trial results for a combined cancer vaccine and immunotherapy program.Well supported16 reports
-
A clinical trial comparing volrustomig against Keytruda was reported, alongside news that Union Investment is an AstraZeneca shareholder.Some support1 report1 development inside
-
Kailera Therapeutics and Hengrui announced a multi-billion-dollar partnership, while Merck seeks pipeline assets to offset revenue decline.Some support1 report
-
Market growth is being driven by advanced therapies involving Pfizer, Novartis, and Merck.Some support1 report4 developments inside
-
Pfizer, Novartis, Merck, and Intravacc are competing in the high-cost gene therapy market, utilizing specialized manufacturing and vaccine production services.Some support1 report
-
Merck incurred losses due to charges related to the acquisition of Cidara Therapeutics.Some support1 report
-
Merck is expanding its lab operations in Singapore.Some support3 reports
No events began in the chosen period. Widen it, or reset.
What's reaching Merck
Recent events traced to Merck, step by stepAround Merck this week
News at the entities that move Merck most-
Moderna OperationalAnalyst downgrades and market challenges are impacting Moderna amid waning demand for COVID-19 vaccines, alongside pipeline successes.Moves Merck
-
Donald Trump OperationalThe Trump administration utilized the Department of Health & Human Services for an AI tool.Moves Merck
-
Bank of America OperationalGoldman Sachs, Morgan Stanley, JPMorgan Chase, and Bank of America are competing in the global investment banking sector.Moves Merck
-
Health Canada StructuralCanadian Blood Services faces union calls for contract termination after Health Canada issued a non-compliance rating.Moves Merck
-
Tempus StructuralLeica Biosystems integrates products from Paige and Tempus AI into its platform, adding Paige products to its AI Store.Moves Merck
-
Pfizer OperationalDave Long trained at Fort Knox after graduating from Boardman High School and later worked for Pfizer.Moves Merck
Connections
The 40 strongest of 235, analyzed from the reporting. The bars show how strongly a change on one side reaches the other.-
Verona Pharma Structural
Merck acquired Verona Pharma for $10 billion, integrating its pipeline and products into Merck's operations.
-
Moderna Operational
Moderna and Merck are actively collaborating on the joint development and clinical trials of personalized mRNA cancer vaccines.
-
Tempus Structural
Tempus supplies diagnostic data and AI tools and partners with Merck on clinical trials.
-
OGN Structural
OGN is a subsidiary of Merck, having been spun off from the parent company in 2021.
-
Dean Y. Li Structural
Dean Y. Li serves as president of Merck Research Laboratories.
-
MSD Structural
MSD functions as the regional name and subsidiary of Merck outside of the US and Canada.
-
Verona Structural
Merck acquired Verona, establishing an ownership relationship that integrates Verona's assets into Merck's drug portfolio.
-
Merck Animal Health Structural
Merck Animal Health operates as a formal division of the larger corporate entity, Merck & Co., Inc.
Show all 40 connections
-
Azad Bonni Structural
Azad Bonni holds the role of senior vice president at Merck.
-
Zoetis Operational
Zoetis and Merck actively compete in the healthcare market, particularly in animal and equine health segments.
-
Donald Trump Operational
Trump's political proposals, executive orders, and policy stances directly influence Merck's market operations, product development, and operational environment.
-
AstraZeneca Operational
AstraZeneca and Merck actively compete in the oncology space while simultaneously engaging in strategic partnerships and profit-sharing agreements.
-
Pfizer Operational
Pfizer and Merck are major pharmaceutical companies engaged in direct competition across key markets including oncology, candidemia, and glaucoma.
-
Rob Davis Structural
Rob Davis serves as the Chairman and CEO of Merck.
-
Bank of America Operational
Bank of America served as the lead financial institution for Merck's $5 billion financing round, establishing a high-stakes operational partnership.
-
Animal Health Structural
Animal Health functions as a specific, integrated business segment within the larger Merck corporate structure.
-
Novartis Operational
The companies are direct competitors in the advanced therapies market and are frequently grouped as top holdings in sector-specific ETFs.
-
Health Canada Structural
Health Canada regulates and approves Merck's pharmaceutical products, enabling their market access in Canada.
-
Narendra Modi Structural
The relationship is defined by the government-led procurement and utilization of Merck's products for the national vaccination campaign.
-
Control Data Corporation Operational
CDC evaluates and recommends Merck's pharmaceutical products, facing current allegations of data falsification.
-
Daiichi Operational
Merck and Daiichi are engaged in a formal co-development partnership for a Phase III clinical study following the acquisition of co-development rights.
-
Vassiliki Karantza Structural
Vassiliki Karantza is employed as an Associate Vice President at Merck.
-
DRC Transactional
Merck provided the Ervebo vaccine for use in a clinical trial conducted in the DRC.
-
CoreWeave Structural
CoreWeave plans to establish its facility on land previously owned by Merck.
-
Robert F. Kennedy Jr. Operational
A promotes B's products through recommendations but also targets B through product liability lawsuits.
-
Hyperion Structural
Hyperion's clinical trial data is utilized by Merck in its drug development and evaluation processes.
-
GSK Operational
GSK and Merck are direct competitors in the market due to their production and sale of combination MMR shots.
-
Hoffmann-La Roche Operational
Roche and Merck are direct competitors in the immuno-oncology and PD-L1 inhibitor markets.
-
Ligand Pharmaceuticals Structural
The companies are in a partnership where Merck funds Ligand's drug development and provides royalty revenue from its portfolio.
-
Veeva Systems Operational
Veeva Systems provides software and strategic services to Merck, which commits to implementing these solutions.
-
Cidara Therapeutics Structural
Merck acquired Cidara Therapeutics, establishing a current parent-subsidiary relationship.
-
Johnson & Johnson Operational
Johnson & Johnson and Merck are major pharmaceutical companies actively competing in specialized drug markets like oncology and PAH.
-
OPKO Health (Ireland) Operational
OPKO Health and Merck are actively collaborating on the development and advancement of an Epstein-Barr virus vaccine candidate.
-
Medicare Transactional
Merck engaged in specific pricing and access negotiations with Medicare regarding its services and products.
-
Eli Lilly and Company Operational
Eli Lilly and Merck are direct, high-stakes competitors in the pharmaceutical market, particularly in oncology and GLP-1 therapeutics.
-
Gilead Sciences Structural
Gilead relies on Merck's products for combination therapies and the companies are actively partnering on new drug development.
-
Amgen Operational
Amgen and Merck are direct competitors in the biosimilar market, large-cap drug sector, and for investor capital.
-
Goldman Sachs Operational
Goldman Sachs actively influences Merck's market valuation and corporate actions through advisory services and analyst ratings.
-
Bristol-Myers Squibb Operational
Both companies actively compete in the oncology sector and are frequently included in the SCHD ETF.
-
Samsung Electronics Structural
Merck supplies high-purity materials and gases to Samsung Electronics.
History
Events by the month they beganSeptember 2026
16 events- Eli Lilly, Novo Nordisk, and Merck are currently competing in the highly competitive GLP-1 obesity market.
- Merck will share clinical trial results at the American Academy of Ophthalmology (AAO) meeting.
- Janus Henderson is backing biotech reverse mergers while dueling drug data emerges between involved companies.
- Bank of America shared insights from Merck's CMO regarding the ongoing financing deal.
- Merck, a New Jersey-based drugmaker, was the subject of an RBC Capital Markets analysis regarding its drug showing non-inferiority to a competitor's product from Hoffmann-La Roche.
- Merck faces sales challenges in China while simultaneously seeking FDA approval for new drugs.
- Pfizer, Johnson & Johnson, and Merck are facing significant industry pressures due to patent cliffs and market pricing demands.
- Moderna and Merck jointly developed and presented intismeran autogene therapy at the ESMO Congress in Madrid.
- ISS research contributed to the formulation of Keytruda, a medical application involving Chief Engineer Ariel Ekblaw and Michael Roberts.
- Amgen and Merck are currently competing against each other in the market for investor capital.
- Merck's Animal Health segment is performing well, and the company discussed transformation during a meeting with Morgan Stanley.
- Dr. Cannon gained experience at Merck, involving Lindus Therapeutics.
- Moderna and Merck announced a landmark moment in vaccine testing, alongside updates regarding personnel at Moderna and Columbia University.
- Merck's stock price increased following positive drug performance involving Summit Therapeutics.
- The Schwab U.S. Dividend Equity ETF now includes Procter & Gamble, Abbott Laboratories, and Merck among its top 10 holdings.
- Moderna and Merck are developing an experimental melanoma vaccine with partners, while concerns about AI models are impacting Gartner's business.
August 2026
32 events- Moderna and Merck announced a partnership on their mRNA cancer vaccine trial, leading to analyst rating hikes.
- Pfizer, Merck, and Amgen are large-cap drugmakers with significant operations in the United States.
- A market rally was observed in the biotech sector, driven by positive cancer vaccine news, causing Eli Lilly shares to rise.
- Eli Lilly, Merck, and Novo Nordisk are competing in the GLP-1 economics market, with Novo Nordisk referencing a SUSE cardiovascular trial.
- Moderna, Tempus, and Merck partnered on the INTerpath-001 trial, which focuses on indications that are covered by Medicare.
- Robert F. Kennedy Jr. collaborated on major cancer vaccine trials while criticizing mRNA technology and its potential funding.
- Financial results and stock performance comparisons among AbbVie, Johnson & Johnson, Eli Lilly, and Merck.
- Merck has set the list price for a drug that received approval from the FDA.
- Moderna combined its vaccine with Merck's Keytruda drug.
- Moderna, Merck, and AbbVie are seeking new revenue streams to offset losses caused by patent expirations.
- Berkshire Hathaway and Warren Buffett commented on the Moderna and Merck partnership, criticizing market speculation while noting positive news regarding the mRNA vaccine collaboration.
- Moderna and Merck are seeking FDA review for a novel cancer treatment, having co-led a Phase 3 mRNA vaccine trial.
- Moderna and Merck announced initial results from a late-stage trial for their novel cancer treatment.
- Moderna, Merck, and Georgetown Lombardi Comprehensive Cancer Center are collaborating on developing a personalized cancer vaccine combination.
- Moderna and Merck developed personalized mRNA cancer vaccine Intismeran following trial success, leading to a surge in Moderna's shares.
- Moderna and Merck announced the successful outcome of their Phase 3 combined treatment trials involving a new cancer vaccine and Keytruda.
- Positive Phase 3 data announced from the combined treatment trials involving Moderna and Merck.
- The new event is a composite of two unrelated stories: FED inaction on inflation and successful cancer therapy trial results involving Moderna and Merck.
- Positive interim readout reported for melanoma trials involving Moderna and Merck.
- Healthcare stocks surged to record highs on August 19, 2026, amid market excitement over drug breakthroughs involving Moderna, Amgen, and Merck.
- Moderna and Merck are developing a combination therapy using Keytruda.
- Andrew Wakefield recommended separating shots in 1998, noting that products would take Merck over a decade to develop.
- Vaccine trial successes boosted Moderna and Merck, while investors awaited Fed minutes amid geopolitical uncertainty in the Middle East and disappointing OpenAI results.
- Google gained permission to buy a $12B stake, coinciding with positive late-stage trial results for a cancer vaccine.
- Moderna and Merck co-developed an experimental cancer vaccine, while also forming a partnership regarding tensor processing units with Google and Marvell Technology.
- Moderna and Merck developed a new therapy.
- Moderna, Merck, and the National Cancer Institute announced successful trial results for a combined cancer vaccine and immunotherapy program.
- A clinical trial comparing volrustomig against Keytruda was reported, alongside news that Union Investment is an AstraZeneca shareholder.
- Kailera Therapeutics and Hengrui announced a multi-billion-dollar partnership, while Merck seeks pipeline assets to offset revenue decline.
- Pfizer, Novartis, Merck, and Intravacc are competing in the high-cost gene therapy market, utilizing specialized manufacturing and vaccine production services.
- Merck incurred losses due to charges related to the acquisition of Cidara Therapeutics.
- Merck is expanding its lab operations in Singapore.
July 2026
1 eventShow 1 earlier month
June 2026
11 events- Bank of America led Merck's $5 billion financing deal, alongside bond sales by automakers, amid market anticipation of FED rate decisions.
- Merck is seeking FDA approval for its drug Winrevair, based on data from the ZENITH, HYPERION, and Stellar studies.
- RFK Jr.'s appointment as HHS Secretary is creating pressure as Medicare price setting and Part D redesign impact the sales and operations of major pharmaceutical companies including Pfizer, Amgen, J&J, Merck, and Eli Lilly.
- Medicare pricing negotiations are impacting major pharmaceutical companies, including AbbVie, Eli Lilly, and Merck, who are seeking pricing exemptions.
- Major pharmaceutical companies, including Pfizer, AstraZeneca, and Merck, announced several new partnerships and acquisitions in the oncology sector.
- Moderna announced a collaboration with Merck KGaA regarding a personalized cancer vaccine platform.
- OPKO Health announced asset sales, advanced an EBV vaccine Phase 1 trial, and saw FDA approval for prostate cancer screening.
- Report covers clinical trials for Mycosis Fungoides involving Bristol-Myers Squibb, Johnson & Johnson, Merck, and Novartis.
- Companies including UnitedHealth Group, Procter & Gamble, Abbott Laboratories, and Merck are noted as being included in high-quality dividend ETFs.
- Novo Nordisk, Merck, and Eli Lilly are noted as large pharmaceutical rivals with recent drug approvals and market presence in the US.
- Market growth is being driven by advanced therapies involving Pfizer, Novartis, and Merck.